Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Genevieve Gauthier, Rebecca Levin, Francis Vekeman, Juan Manuel Reyes, Esteban Chiarello & Dario Ponce de Leon. (2021) Treatment patterns and sequencing in patients with rheumatic diseases: a retrospective claims data analysis. Current Medical Research and Opinion 37:12, pages 2185-2196.
Read now
Read now
Jean-Guillaume Letarouilly, Jean-Hugues Salmon & René-Marc Flipo. (2021) Factors affecting persistence with biologic treatments in patients with rheumatoid arthritis: a systematic literature review. Expert Opinion on Drug Safety 20:9, pages 1087-1094.
Read now
Read now
Maurizio Benucci, Arianna Damiani, Mariangela Manfredi, Maria Infantino, Valentina Grossi & Francesca Li Gobbi. (2019) Abatacept: from a budget impact model to cost-effectiveness analysis – data from RCT and real life. ClinicoEconomics and Outcomes Research 11, pages 405-409.
Read now
Read now
Jéssica Barreto Ribeiro dos Santos, Augusto Afonso Guerra Junior, Michael Ruberson Ribeiro da Silva, Alessandra Maciel Almeida, Francisco de Assis Acurcio & Juliana Alvares-Teodoro. (2019) First line of biological drugs in rheumatoid arthritis: a medication persistence analysis. Expert Review of Clinical Pharmacology 12:4, pages 363-370.
Read now
Read now
Walid Fakhouri, Pedro Lopez-Romero, Silvia Antonelli, Serena Losi, Veronica Rogai, Stefano Buda, Diego Sangiorgi, Valentina Perrone & Luca Degli Esposti. (2018) Treatment patterns, health care resource utilization and costs of rheumatoid arthritis patients in Italy: findings from a retrospective administrative database analysis. Open Access Rheumatology: Research and Reviews 10, pages 103-111.
Read now
Read now
Articles from other publishers (10)
Ashley Fletcher, Marissa Lassere, Lyn March, Catherine Hill, Claire Barrett, Graeme Carroll & Rachelle Buchbinder. (2022) Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia. Rheumatology 61:10, pages 3939-3951.
Crossref
Crossref
Johan Dalén, Anushri Chitkara, Axel Svedbom, Tor Olofsson, Amy Puenpatom, Christopher M. Black & Zaina P. Qureshi. (2021) Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study. Advances in Therapy 39:6, pages 2468-2486.
Crossref
Crossref
Lynn Weekes. 2020. Biologics, Biosimilars, and Biobetters. Biologics, Biosimilars, and Biobetters
237
251
.
Johan Dalén, Karin Luttropp, Axel Svedbom, Christopher M. Black & Sumesh Kachroo. (2020) Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-α Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study. Advances in Therapy 37:9, pages 3746-3760.
Crossref
Crossref
Karel Kostev & Louis Jacob. (2019) Persistence and treatment-free interval in patients being prescribed biological drugs in rheumatology practices in Germany. European Journal of Clinical Pharmacology 75:5, pages 717-722.
Crossref
Crossref
Ibrahim KhilfehEric GuyetteJohn WatkinsDan DanielsonDavid Gross & Kai Yeung. (2019) Adherence, Persistence, and Expenditures for High-Cost Anti-Inflammatory Drugs in Rheumatoid Arthritis: An Exploratory Study. Journal of Managed Care & Specialty Pharmacy 25:4, pages 461-467.
Crossref
Crossref
Fabrizio Cantini & Maurizio Benucci. (2019) Additional comment to: ‘Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?’ by Scherlinger and Schaeverbeke. Annals of the Rheumatic Diseases 78:4, pages e25-e25.
Crossref
Crossref
Louis Jacob, Thomas Chevalier & Karel Kostev. (2018) Persistence with biological drugs in patients treated in rheumatology practices in Germany. Rheumatology International 39:3, pages 525-531.
Crossref
Crossref
Nikos Maniadakis, Emese Toth, Michael Schiff, Xuan Wang, Maria Nassim, Boglarka Szegvari, Irina Mountian & Jeffrey R. Curtis. (2018) A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences. Advances in Therapy 35:9, pages 1333-1355.
Crossref
Crossref
Dimitrios A. Pappas, Joel M. Kremer, Jenny Griffith, George Reed, Bob Salim, Chitra Karki & Vishvas Garg. (2017) Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry. Rheumatology and Therapy 4:2, pages 375-389.
Crossref
Crossref